Detalles de la búsqueda
1.
Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma.
Melanoma Manag
; 6(2): MMT20, 2019 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-31406564
2.
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.
J Immunother Cancer
; 6(1): 19, 2018 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29510745
3.
Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Cancer Biother Radiopharm
; 22(2): 185-93, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17600465
4.
Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma.
Cancer Biother Radiopharm
; 22(3): 309-21, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17651037
5.
Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09.
Cancer Biother Radiopharm
; 21(2): 130-7, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16706633
6.
Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes?
Cancer Biother Radiopharm
; 20(4): 373-8, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16114985
7.
Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
Cancer Biother Radiopharm
; 30(5): 187-94, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26083950
8.
Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: a phase II trial of the cancer biotherapy research group.
Cancer Biother Radiopharm
; 18(5): 727-33, 2003 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-14629821
9.
Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer.
Cancer Biother Radiopharm
; 19(6): 730-7, 2004 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-15665620
10.
Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
Cancer Biother Radiopharm
; 19(5): 570-80, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15650449
11.
Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas.
Cancer Biother Radiopharm
; 19(5): 581-8, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15650450
12.
Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis.
Cancer Biother Radiopharm
; 19(5): 658-65, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15650459
13.
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Cancer Biother Radiopharm
; 17(2): 165-73, 2002 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-12030110
14.
Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
Cancer Biother Radiopharm
; 17(1): 51-66, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11915174
15.
High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines.
Cancer Biother Radiopharm
; 29(2): 53-7, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24380630
16.
Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
J Immunother
; 35(8): 641-9, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22996370
17.
Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines.
Cancer Biother Radiopharm
; 26(4): 407-15, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21812653
18.
Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine.
Cancer Biother Radiopharm
; 25(5): 553-7, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20849310
19.
Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Cancer Biother Radiopharm
; 24(3): 311-9, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19538053
20.
Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma.
J Immunother
; 27(5): 398-404, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15314549
Resultados
1 -
20
de 20
1
Próxima >
>>